Market Research Logo

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Review, H1 2016’, provides in depth analysis on Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted pipeline therapeutics.

The report provides comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
  • The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


According to Global Markets Direct's, recently published report 'Coagulation Factor XI – Pipeline Review, H1 2016'; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) pipeline Target constitutes close to 11 molecules. Out of which approximately 10 molecules are developed by Companies and remaining by the Universities/Institutes.

Furthermore, Global Markets Direct says; Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

The report 'Coagulation Factor XI – Pipeline Review, H1 2016' outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 4 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Introduction
Global Markets Direct Report Coverage
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) Overview
Therapeutics Development
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Stage of Development
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Therapy Area
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Indication
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Companies
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Products under Development by Universities/Institutes
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Companies Involved in Therapeutics Development
Bayer AG
Bristol-Myers Squibb Company
Cambryn Biologics LLC
eXithera Pharmaceuticals, Inc
Ionis Pharmaceuticals, Inc.
LegoChem Biosciences, Inc
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Drug Profiles
AB-022 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-262084 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-654457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
coagulation factor XI (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 to Inhibit Factor XIa for Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activated Factor XI for Bleeding Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Blood Factor XIa for CAHD and Stroke - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Cardiovascular - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Factor XIa for Stroke and Thrombosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Dormant Projects
Coagulation Factor XI (Plasma Thromboplastin Antecedent or EC 3.4.21.27) - Featured News & Press Releases
Oct 30, 2015: Isis Pharmaceuticals Initiates Phase 2 Study of ISIS-FXI Rx in Patients with End-Stage Renal Disease on Hemodialysis
Feb 24, 2015: Bayer HealthCare and Aronora Establish Partnership for the Pre-Clinical Manufacturing of AB-022
Dec 07, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx for the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Nov 18, 2014: Isis Pharmaceuticals To Host Webcast To Discuss ISIS-FXI Rx Data Presented At The ASH Annual Meeting
May 22, 2014: Isis Pharmaceuticals Reports Positive Phase 2 Data for ISIS-FXI Rx in the Prevention of Venous Thrombosis in Patients Undergoing Total Knee Replacement Surgery
Apr 19, 2013: CML HealthCare's Subsidiary Hemostasis Reference Labs Receives Contract Extension From Isis Pharma
Oct 29, 2012: Isis Pharma Initiates Phase II Study Of ISIS-FXIRX In Patients Undergoing Knee Replacement Surgery
Dec 12, 2011: Isis Reports Positive Phase I Data Demonstrating ISIS-FXIRx Reduces Factor XI Activity Without Bleeding
Feb 02, 2011: Isis Initiates Phase I Clinical Trial Of ISIS-FXIRx To Treat Clotting Disorders
Dec 03, 2009: Isis Pharmaceuticals Adds ISIS-FXIRx To Development Pipeline For The Treatment Of Clotting Disorders
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Bayer AG, H1 2016
Pipeline by Bristol-Myers Squibb Company, H1 2016
Pipeline by Cambryn Biologics LLC, H1 2016
Pipeline by eXithera Pharmaceuticals, Inc, H1 2016
Pipeline by Ionis Pharmaceuticals, Inc., H1 2016
Pipeline by LegoChem Biosciences, Inc, H1 2016
Dormant Projects, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report